{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:00:24Z","timestamp":1761156024538},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.bone.2015.04.013","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T23:01:05Z","timestamp":1446764465000},"page":"150-156","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Emerging therapeutic concepts for muscle and bone preservation\/building"],"prefix":"10.1016","volume":"80","author":[{"given":"Juliet","family":"Compston","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2015.04.013_bb0005","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/gerona\/glt093","article-title":"Public health impact of osteoporosis","volume":"68","author":"Cauley","year":"2013","journal-title":"J. Gerontol. A Biol. Sci. Med."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jbmr.5650050402","article-title":"Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels","volume":"5","author":"Eriksen","year":"1990","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0015","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1164\/rccm.200512-1943OC","article-title":"Osteoclastogenesis during infective exacerbations in patients with cystic fibrosis","volume":"174","author":"Shead","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrrheum.2009.259","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"6","author":"Compston","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0025","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0169-6009(89)90039-1","article-title":"Structural mechanisms of trabecular bone loss in man","volume":"6","author":"Compston","year":"1989","journal-title":"Bone Miner."},{"issue":"12","key":"10.1016\/j.bone.2015.04.013_bb0030","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00198-012-1935-8","article-title":"Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"23","author":"Roux","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/rheumatology\/ket236","article-title":"Safety issues with bisphosphonate therapy for osteoporosis","volume":"53","author":"Suresh","year":"2014","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0045","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S8756-3282(01)00485-9","article-title":"Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women","volume":"29","author":"Roschger","year":"2001","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0055","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00198-008-0725-9","article-title":"Spectroscopic markers of bone quality in alendronate-treated postmenopausal women","volume":"20","author":"Boskey","year":"2009","journal-title":"Osteoporos. Int."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/jbmr.1501","article-title":"Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization","volume":"27","author":"Bala","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-012-2202-8","article-title":"Effects of 3years treatment with once-yearly zoledronic acid on the kinetics of bone matrix maturation in osteoporotic patients","volume":"24","author":"Gamsjaeger","year":"2013","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0070","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/jbmr.1780","article-title":"Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort","volume":"28","author":"Misof","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0075","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jbmr.2035","article-title":"Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study","volume":"29","author":"Misof","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0080","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/jbmr.1572","article-title":"Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces","volume":"27","author":"Hofstetter","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1359\/jbmr.090711","article-title":"Risedronate reduces intracortical porosity in women with osteoporosis","volume":"25","author":"Borah","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0090","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jbmr.2101","article-title":"Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women","volume":"29","author":"Bala","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0100","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2015.04.013_bb0105","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/jbmr.157","article-title":"A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover","volume":"25","author":"Burghardt","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bone.2013.07.011","article-title":"Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab","volume":"56","author":"Genant","year":"2013","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jbmr.2024","article-title":"Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab","volume":"29","author":"Keaveny","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jbmr.2325","article-title":"Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis","volume":"30","author":"Poole","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb9010","article-title":"Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension","volume":"28","author":"Papapoulos","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin. Endocrinol. (Oxf)"},{"issue":"7","key":"10.1016\/j.bone.2015.04.013_bb8000","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in Cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J. Bone Miner Res."},{"issue":"9","key":"10.1016\/j.bone.2015.04.013_bb8010","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1002\/jbmr.2236","article-title":"Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension","volume":"29","author":"Brown","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/8756-3282(93)90190-L","article-title":"Early histomorphometric changes in response to parathyroid hormone in osteoporosis: evidence for de novo bone formation on quiescent surfaces","volume":"14","author":"Hodsman","year":"1993","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.013_bb0140","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1359\/jbmr.060314","article-title":"Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis","volume":"21","author":"Ma","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0145","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1210\/jc.2012-1262","article-title":"Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial","volume":"97","author":"Dempster","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2015.04.013_bb0150","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0155","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1\u201334) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb6000","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(00)00430-0","article-title":"Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fascicularis)","volume":"28","author":"Perome","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.013_bb0160","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bone.2010.11.012","article-title":"Time-dependent changes in skeletal response to teriparatide: escalating vs. constant dose teriparatide (PTH 1\u201334) in osteoporotic women","volume":"48","author":"Yu","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0170","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Treatment of osteoporosis with parathyroid hormone study group. Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0175","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2015.04.013_bb0180","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0185","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1359\/jbmr.090820","article-title":"Quantitative computed tomographic assessment of the effects of 24months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study","volume":"25","author":"Borggrefe","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bone.2011.10.002","article-title":"Femoral strength in osteoporotic women treated with teriparatide or alendronate","volume":"50","author":"Keaveny","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.013_bb0195","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.bone.2013.11.011","article-title":"Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment","volume":"59","author":"Ma","year":"2014","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0200","doi-asserted-by":"crossref","first-page":"e16190","DOI":"10.1371\/journal.pone.0016190","article-title":"Targeted regeneration of bone in the osteoporotic human femur","volume":"6","author":"Poole","year":"2011","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bone.2015.04.013_bb0205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.198","article-title":"Effects of 1year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate","volume":"25","author":"Misof","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0210","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1210\/jc.2004-2489","article-title":"Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the fracture prevention trial","volume":"90","author":"Paschalis","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2015.04.013_bb0215","first-page":"E146","article-title":"Role for parathyroid hormone in mechanical responsiveness of rat bone","volume":"274","author":"Chow","year":"1998","journal-title":"Am. J. Physiol."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0220","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/jbmr.1784","article-title":"Differing effects of PTH 1\u201334, PTH 1\u201384, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: an 18-month open-labeled observational study using HR-pQCT","volume":"28","author":"Hansen","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb9000","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb9005","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2015.04.013_bb0225","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1359\/JBMR.050405","article-title":"Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone","volume":"20","author":"Farley","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0230","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1359\/jbmr.090601","article-title":"Could strontium ranelate have a synergistic role in the treatment of osteoporosis?","volume":"24","author":"Blake","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0235","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0240","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/jbmr.2074","article-title":"Bone histomorphometry of transiliac paired bone biopsies after 6 or 12months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate","volume":"29","author":"Chavassieux","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2004.09.020","article-title":"Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL\/OPG ratio","volume":"36","author":"Kiviranta","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.013_bb0250","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jbmr.1475","article-title":"Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys","volume":"27","author":"Masarachia","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0255","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0260","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bone.2011.06.014","article-title":"The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking","volume":"49","author":"Leung","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2015.04.013_bb0265","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0270","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00223-012-9673-7","article-title":"Effects of odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study","volume":"92","author":"Fratzl-Zelman","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0275","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","article-title":"Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey","volume":"27","author":"Cusick","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bone.2015.04.013_bb0280","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jbmr.1475","article-title":"Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys","volume":"27","author":"Masarachia","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0285","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/jbmr.2211","article-title":"Inhibition of cathepsin k increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys","volume":"29","author":"Pennypacker","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0290","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bone.2013.06.008","article-title":"Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate","volume":"56","author":"Williams","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0295","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.bone.2013.06.011","article-title":"High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate","volume":"56","author":"Cabal","year":"2013","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0300","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1210\/jc.2012-2972","article-title":"Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial","volume":"98","author":"Brixen","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.bone.2015.04.013_bb0305","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jbmr.2194","article-title":"Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength","volume":"29","author":"Cheung","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0310","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jbmr.2292","article-title":"Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women \u2014 results of a 2-year placebo-controlled trial","volume":"30","author":"Engelke","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.bone.2015.04.013_bb3000","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.3586","article-title":"Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-\u03baB","volume":"20","author":"Yu","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.bone.2015.04.013_bb0315","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bone.2015.04.013_bb0320","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res."},{"key":"10.1016\/j.bone.2015.04.013_bb0325","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0330","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0335","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2015.04.013_bb0340","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/jbmr.2152","article-title":"Tissue\u2010level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody","volume":"29","author":"Ominsky","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"10","key":"10.1016\/j.bone.2015.04.013_bb0345","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/jbmr.2259","article-title":"Sclerostin deficiency is linked to altered bone composition","volume":"29","author":"Hassler","year":"2014","journal-title":"J Bone Miner Res."},{"issue":"7","key":"10.1016\/j.bone.2015.04.013_bb0350","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.2188","article-title":"Bone matrix quality after sclerostin antibody treatment","volume":"29","author":"Ross","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2015.04.013_bb0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0360","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"4","key":"10.1016\/j.bone.2015.04.013_bb0365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2015.04.013_bb0370","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9suppl 1","key":"10.1016\/j.bone.2015.04.013_bb2000","article-title":"Effects of 2 years of treatment With romosozumab followed by 1 Year of denosumab or placebo in postmenopausal women with low bone mineral density","volume":"29","author":"McClung","year":"2014","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2015.04.013_bb0375","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821500126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S875632821500126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T07:51:33Z","timestamp":1718178693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S875632821500126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":83,"alternative-id":["S875632821500126X"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2015.04.013","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapeutic concepts for muscle and bone preservation\/building","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2015.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}